246 related articles for article (PubMed ID: 33783763)
21. Chlorogenic acid administered intrathecally alleviates mechanical and cold hyperalgesia in a rat neuropathic pain model.
Hara K; Haranishi Y; Kataoka K; Takahashi Y; Terada T; Nakamura M; Sata T
Eur J Pharmacol; 2014 Jan; 723():459-64. PubMed ID: 24184666
[TBL] [Abstract][Full Text] [Related]
22. A multi-target approach for pain treatment: dual inhibition of fatty acid amide hydrolase and TRPV1 in a rat model of osteoarthritis.
Malek N; Mrugala M; Makuch W; Kolosowska N; Przewlocka B; Binkowski M; Czaja M; Morera E; Di Marzo V; Starowicz K
Pain; 2015 May; 156(5):890-903. PubMed ID: 25719612
[TBL] [Abstract][Full Text] [Related]
23. The anandamide transport inhibitor AM404 reduces ethanol self-administration.
Cippitelli A; Bilbao A; Gorriti MA; Navarro M; Massi M; Piomelli D; Ciccocioppo R; Rodríguez de Fonseca F
Eur J Neurosci; 2007 Jul; 26(2):476-86. PubMed ID: 17650118
[TBL] [Abstract][Full Text] [Related]
24. Reciprocal changes in vanilloid (TRPV1) and endocannabinoid (CB1) receptors contribute to visceral hyperalgesia in the water avoidance stressed rat.
Hong S; Fan J; Kemmerer ES; Evans S; Li Y; Wiley JW
Gut; 2009 Feb; 58(2):202-10. PubMed ID: 18936104
[TBL] [Abstract][Full Text] [Related]
25. Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.
Haller VL; Cichewicz DL; Welch SP
Eur J Pharmacol; 2006 Sep; 546(1-3):60-8. PubMed ID: 16919265
[TBL] [Abstract][Full Text] [Related]
26. The endocannabinoid transport inhibitor AM404 modulates nociception in cholestasis.
Hasanein P
Neurosci Lett; 2009 Oct; 462(3):230-4. PubMed ID: 19616063
[TBL] [Abstract][Full Text] [Related]
27. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.
Lastres-Becker I; de Miguel R; De Petrocellis L; Makriyannis A; Di Marzo V; Fernández-Ruiz J
J Neurochem; 2003 Mar; 84(5):1097-109. PubMed ID: 12603833
[TBL] [Abstract][Full Text] [Related]
28. Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide].
La Rana G; Russo R; Campolongo P; Bortolato M; Mangieri RA; Cuomo V; Iacono A; Raso GM; Meli R; Piomelli D; Calignano A
J Pharmacol Exp Ther; 2006 Jun; 317(3):1365-71. PubMed ID: 16510698
[TBL] [Abstract][Full Text] [Related]
29. Endogenous anandamide and cannabinoid receptor-2 contribute to electroacupuncture analgesia in rats.
Chen L; Zhang J; Li F; Qiu Y; Wang L; Li YH; Shi J; Pan HL; Li M
J Pain; 2009 Jul; 10(7):732-9. PubMed ID: 19409856
[TBL] [Abstract][Full Text] [Related]
30. Augmentation of endogenous cannabinoid tone modulates lipopolysaccharide-induced alterations in circulating cytokine levels in rats.
Roche M; Kelly JP; O'Driscoll M; Finn DP
Immunology; 2008 Oct; 125(2):263-71. PubMed ID: 18393970
[TBL] [Abstract][Full Text] [Related]
31. Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors.
Desroches J; Charron S; Bouchard JF; Beaulieu P
Neuropharmacology; 2014 Feb; 77():441-52. PubMed ID: 24148808
[TBL] [Abstract][Full Text] [Related]
32. Cannabinoid subtype-2 receptors modulate the antihyperalgesic effect of WIN 55,212-2 in rats with neuropathic spinal cord injury pain.
Ahmed MM; Rajpal S; Sweeney C; Gerovac TA; Allcock B; McChesney S; Patel AU; Tilghman JI; Miranpuri GS; Resnick DK
Spine J; 2010 Dec; 10(12):1049-54. PubMed ID: 20920894
[TBL] [Abstract][Full Text] [Related]
33. Spinal cannabinoid CB2 receptors as a target for neuropathic pain: an investigation using chronic constriction injury.
Brownjohn PW; Ashton JC
Neuroscience; 2012 Feb; 203():180-93. PubMed ID: 22210507
[TBL] [Abstract][Full Text] [Related]
34. Spinal anandamide produces analgesia in neuropathic rats: possible CB(1)- and TRPV1-mediated mechanisms.
Starowicz K; Makuch W; Osikowicz M; Piscitelli F; Petrosino S; Di Marzo V; Przewlocka B
Neuropharmacology; 2012 Mar; 62(4):1746-55. PubMed ID: 22178705
[TBL] [Abstract][Full Text] [Related]
35. Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats.
Sagar DR; Kelly S; Millns PJ; O'Shaughnessey CT; Kendall DA; Chapman V
Eur J Neurosci; 2005 Jul; 22(2):371-9. PubMed ID: 16045490
[TBL] [Abstract][Full Text] [Related]
36. Combined inhibition of monoacylglycerol lipase and cyclooxygenases synergistically reduces neuropathic pain in mice.
Crowe MS; Leishman E; Banks ML; Gujjar R; Mahadevan A; Bradshaw HB; Kinsey SG
Br J Pharmacol; 2015 Apr; 172(7):1700-12. PubMed ID: 25393148
[TBL] [Abstract][Full Text] [Related]
37. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain.
Kinsey SG; Long JZ; O'Neal ST; Abdullah RA; Poklis JL; Boger DL; Cravatt BF; Lichtman AH
J Pharmacol Exp Ther; 2009 Sep; 330(3):902-10. PubMed ID: 19502530
[TBL] [Abstract][Full Text] [Related]
38. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.
Deng L; Guindon J; Cornett BL; Makriyannis A; Mackie K; Hohmann AG
Biol Psychiatry; 2015 Mar; 77(5):475-87. PubMed ID: 24853387
[TBL] [Abstract][Full Text] [Related]
39. Effects of intrathecal and intracerebroventricular administration of luteolin in a rat neuropathic pain model.
Hara K; Haranishi Y; Terada T; Takahashi Y; Nakamura M; Sata T
Pharmacol Biochem Behav; 2014 Oct; 125():78-84. PubMed ID: 25196931
[TBL] [Abstract][Full Text] [Related]
40. Probable involvement of Ca(2+)-activated Cl(-) channels (CaCCs) in the activation of CB1 cannabinoid receptors.
Romero TR; Pacheco Dda F; Duarte ID
Life Sci; 2013 May; 92(14-16):815-20. PubMed ID: 23123446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
